Cheryl Sew Hoy Co-Founded Tiny Health Secures $33M in Series B Funding

Tiny Health, an Austin, TX-based microbiome intelligence platform advancing gut, and vaginal microbiome testing across the lifespan, has secured $33 million in Series B funding led by B Capital, bringing total funding to $46 million.

The round also saw participation from existing investors Spero Ventures, The Venture City, Overwater Ventures, and others, and new investors Black Opal Ventures, Denver Ventures, Pave Health Ventures, Alumni Ventures, Gaingels, and Pari Passu Ventures. Nick Whitehead, Senior Principal at B Capital, will join the Tiny Health Board of Directors.

The company will use the funds to support clinical research and studies, expand education for healthcare professionals, and grow its B2B platform, Powered by Tiny. It will also develop TinyAI, an AI tool trained on nearly 200,000 microbiome profiles to provide personalized guidance based on users’ results.

What is Tiny Health?

Tiny Health provides gut and vaginal microbiome testing designed to support health insights across different stages of life.

Its platform uses shotgun metagenomics, proprietary AI and a large longitudinal microbiome dataset to analyze microorganisms and provide information about factors such as metabolic capacity, immune markers and pathogenic organisms.

Read More:Efficient Computer Gats $97M in Series B Funding Led by TQ Ventures

The company also operates Powered by Tiny, a B2B platform, and is developing TinyAI to provide personalized guidance based on individual microbiome results.

How Much Funding Has Tiny Health Secured?

Tiny Health has secured $33 million in its latest Series B funding round.

The latest round brings the company’s total funding secured to $46 million.

The company was founded in 2020.

Who Invested in Tiny Health’s Series B?

The Series B round was led by B Capital.

Existing investors included:

• Spero Ventures
• The Venture City
• Overwater Ventures
• Other existing investors

New investors included:

• Black Opal Ventures
• Denver Ventures
• Pave Health Ventures
• Alumni Ventures
• Gaingels
• Pari Passu Ventures

Why the Funding Matters

Tiny Health will use the funding to advance clinical research and interventional studies.

The company also plans to expand healthcare practitioner education, scale its Powered by Tiny B2B platform and accelerate development of TinyAI.

Tiny Health will also commit $5 million to its Microbiome Research Program to support researchers, clinicians and scientific partners working on microbiome health.

Who founded Tiny Health?

Tiny Health was founded in 2020 by Cheryl Sew Hoy and is headquartered in Austin, Texas.

The company was built by microbiome scientists and physicians.

“We founded Tiny Health because the science is so impactful, the need is urgent, and no one else was building for the whole lifespan,” said Cheryl Sew Hoy, CEO and Founder of Tiny Health. “What started as a solution for my own family has become the infrastructure for an entire industry.

“Tiny Health believes the next breakthroughs in microbiome science will come from bringing more researchers and institutions into the field,” said Kimberley Sukhum, PhD, Chief Science Officer at Tiny Health. “This investment will help generate new evidence and foster collaborations across the scientific community, building on Tiny Health’s growing body of peer-reviewed research, and its commitment to advancing rigorous, accessible microbiome science.”

Market and Business Growth

Tiny Health has built a proprietary dataset containing nearly 200,000 microbiome profiles.

The company has published four scientific papers and has a second randomized controlled trial underway. Its research covers areas including early-life health, inflammatory bowel disease, menopause, GLP-1 treatments and oncology drug response.

A 2025 randomized controlled trial published in Pediatric Allergy and Immunology reported that targeted microbiome interventions reduced infants’ odds of developing eczema by 83%.

Tiny Health’s testing platform analyzes more than 120,000 genomes and identifies microbes down to the strain level.

The company is also developing tools including Gut Microbiome Age, Gut Resilience and Gut Body Connections for longevity and healthy aging.

What Happens Next?

Tiny Health plans to expand its clinical research, practitioner education and B2B platform while continuing development of TinyAI.

The company will also use its Microbiome Research Program to support further research into microbiome-based interventions and precision health.

Read More:Destro AI Secures $8M in Seed Funding Round